TVRD
TVRD clinical trials: Tvardi Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Tvardi Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 4
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
TVRD on the catalyst calendar · TVRD registry changes
- Primary completion May 25, 2027Sponsor estimatePhase 1/Phase 2NCT05440708A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable...Tvardi Therapeutics, Incorporated · Hepatocellular CarcinomaRecruitingTVRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2024ActualPhase 1NCT05384119Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerTvardi Therapeutics, Incorporated · Breast CancerTerminatedTVRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 14, 2025ActualPhase 2NCT05671835Study of TTI-101 in Participants With Idiopathic Pulmonary FibrosisTvardi Therapeutics, Incorporated · Idiopathic Pulmonary FibrosisCompletedTVRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 24, 2024ActualPhase 1NCT03195699Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced CancersTvardi Therapeutics, Incorporated · Breast CancerCompletedTVRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2029Sponsor estimatePhase 1NCT06141031Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal AdenocarcinomaWashington University School of Medicine · Pancreatic CancerRecruitingTVRDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 23, 2025ActualPhase 1/Phase 2NCT05668949Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy...M.D. Anderson Cancer Center · Head and Neck Squamous Cell CarcinomaWithdrawnTVRDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 13, 2025ActualEarly Phase 1NCT05845307Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell...M.D. Anderson Cancer Center · Squamous Cell Carcinoma of Head and NeckWithdrawnTVRDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner